Læknablaðið - apr. 2019, Side 16

168 LÆKNAblaðið 2019/105
R A N N S Ó K N
Barst til blaðsins 23. júlí 2018, samþykkt til birtingar 27. febrúar 2019.
1. Bjornsson G. Prevalence and causes of blindness in
Iceland, with special reference to glaucoma simplex. Am J
Ophthalmol 1955; 39: 202-8.
2. Gunnlaugsdottir E, Arnarsson A, Jonasson F. Prevalence
and causes of visual impairment and blindness in
Icelanders aged 50 years and older: The Reykjavik Eye
Study. Acta Ophthalmolog 2008 ; 86:778-85.
3. Jonasson F, Damji KF, Arnarsson A, Sverrisson T, Wang
L, Sasaki H, et al. Prevalence of open-angle glaucoma in
Iceland: The Reykjavik Eye Study. Eye (London, England)
2003; 17: 747-53.
4. Weinreb RN, Aung T, Medeiros FA. The pathophysiology
and treatment of glaucoma: a review. JAMA 2014; 311:
1901-11.
5. Gottfredsdottir MS, Allingham RR, Shields MB.
Physicians‘ guide to interactions between glaucoma and
systemic medications. J Glaucoma 1997; 6: 377-83..
6. Hovstadius B, Hovstadius K, Astrand B, Petersson G.
Increasing polypharmacy - an individual-based study of
the Swedish population 2005-2008. BMC Clin Pharmacol
2010; 10: 16.
7. Hansdóttir H, Guðmannsson PG. Lyfjanotkun á hjúkr-
unarheimilum á Íslandi 2002-2004. Lýsandi rannsókn.
Læknablaðið 2013; 99: 383-9.
8. Broadway DC, Cate H. Pharmacotherapy and adherence
issues in treating elderly patients with glaucoma. Drugs
Aging 2015; 32: 569-81.
9. Sleath B, Robin AL, Covert D, Byrd JE, Tudor G, Svarstad
B. Patient-reported behavior and problems in using
glaucoma medications. Ophthalmol 2006; 113: 431-6.
10. Novack GD, Robin AL. Ocular pharmacology. J Clin
Pharmacol 2016; 56: 517-27.
11. Flach AJ. The importance of eyelid closure and
nasolacrimal occlusion following the ocular instillation
of topical glaucoma medications, and the need for the
universal inclusion of one of these techniques in all patient
treatments and clinical studies. Transa Am Ophthalmol
Soc 2008; 106: 138-48.
12. Fraunfelder FT. Extraocular fluid dynamics: how best to
apply topical ocular medication. Transa Am Ophthalmol
Soc 1976; 74: 457-87.
13. Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in
glaucoma patients. Ophthalmol 1984; 91: 1361-3.
14. Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP.
Improving the therapeutic index of topically applied
ocular drugs. Arch Ophthalmol 1984; 102: 551-3.
15. Chung HJ, Hwang HB, Lee NY. The association between
primary open-angle glaucoma and blood pressure: two
aspects of hypertension and hypotension. BioMed Res Int
2015; 2015: 827516.
16. Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio
R, Varotto A. Vascular risk factors for primary open angle
glaucoma: the Egna-Neumarkt Study. Ophthalmol 2000;
107: 1287-93.
17. Razeghinejad MR, Pro MJ, Katz LJ. Non-steroidal drug-
induced glaucoma. Eye (London, England) 2011; 25: 971-
80.
18. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE.
The anticholinergic risk scale and anticholinergic adverse
effects in older persons. Arch Intern Med 2008; 168: 508-13.
19. Garbe E, LeLorier J, Boivin JF, Suissa S. Risk of ocular
hypertension or open-angle glaucoma in elderly patients
on oral glucocorticoids. Lancet 1997; 350: 979-82.
20. Alm A, Camras CB, Watson PG. Phase III latanoprost
studies in Scandinavia, the United Kingdom and the
United States. Surv Ophthalmol 1997; 41 Suppl 2: S105-10.
21. DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh
AM, Felix C. Efficacy and safety of bimatoprost in patients
with elevated intraocular pressure: a 30-day comparison
with latanoprost. Surv Ophthalmol 2001; 45 Suppl 4: S353-
60.
22. Miyake K, Ota I, Maekubo K, Ichihashi S, Miyake S.
Latanoprost accelerates disruption of the blood-aqueous
barrier and the incidence of angiographic cystoid macular
edema in early postoperative pseudophakias. Arch
Ophthalmol 1999; 117: 34-40.
23. Maenpaa J, Pelkonen O. Cardiac safety of ophthalmic
timolol. Expert Opin Drug saf 2016; 15: 1549-61.
24. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB,
Kuritsky JN. Adverse respiratory and cardiovascular
events attributed to timolol ophthalmic solution, 1978-
1985. Am J Ophthalmol 1986; 102: 606-11.
25. Van Buskirk EM. Adverse reactions from timolol
administration. Ophthalmol 1980; 87: 447-50.
26. Freedman SF, Freedman NJ, Shields MB, Lobaugh B,
Samsa GP, Keates EU, et al. Effects of ocular carteolol and
timolol on plasma high-density lipoprotein cholesterol
level. Am J Ophthalmol 1993; 116: 600-11.
27. Velde TM, Kaiser FE. Ophthalmic timolol treatment caus-
ing altered hypoglycemic response in a diabetic patient.
Arch Intern Med 1983; 143: 1627.
28. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li
Y, et al. Prevalence and incidence trends for diagnosed
diabetes among adults aged 20 to 79 years, United States,
1980-2012. JAMA 2014; 312: 1218-26.
29. Korte JM, Kaila T, Saari KM. Systemic bioavailability
and cardiopulmonary effects of 0.5% timolol eyedrops.
Graefes Arch Clin Exp Ophthalmol 2002; 240: 430-5.
30. Nieminen T, Uusitalo H, Turjanmaa V, Bjarnhall G,
Hedenstrom H, Maenpaa J, et al. Association between low
plasma levels of ophthalmic timolol and haemodynamics
in glaucoma patients. Eur J Clin Pharmacol 2005; 61: 369-
74.
31. Edeki TI, He H, Wood AJ. Pharmacogenetic explanation
for excessive beta-blockade following timolol eye drops.
Potential for oral-ophthalmic drug interaction. JAMA
1995; 274: 1611-3.
32. Maenpaa J, Volotinen-Maja M, Kautiainen H, Neuvonen
M, Niemi M, Neuvonen PJ, et al. Paroxetine markedly
increases plasma concentrations of ophthalmic timolol;
CYP2D6 inhibitors may increase the risk of cardiovascular
adverse effects of 0.5% timolol eye drops. Drug Metabol
Disp: Biol Fate Chemicals 2014; 42: 2068-76.
33. Samuelsson O, Zoega H, Gudmundsson A, Halldorsson
M. Algengi geðlyfjanotkunar eldri Íslendinga utan stofn-
ana. Læknablaðið 2009; 95: 11-7.
34. Pringle SD, MacEwen CJ. Severe bradycardia due to inter-
action of timolol eye drops and verapamil. BMJ 1987; 294:
155-6.
35. Salim S, Shields MB. Glaucoma and systemic diseases.
Surv Ophthalmol 2010; 55: 64-77.
36. Maren TH, Conroy CW, Wynns GC, Levy NS. Ocular
absorption, blood levels, and excretion of dorzolamide,
a topically active carbonic anhydrase inhibitor. J Ocul
Pharmacol Ther 1997; 13: 23-30.
37. Buclin T, Biollaz J, Lippa EA, Brunner-Ferber F, van Melle
G, Munafo A, et al. Absence of metabolic effects of the
topical carbonic anhydrase inhibitors MK-927 and sezola-
mide during two-week ocular administration to normal
subjects. Clini Pharmacol Ther 1991; 49: 665-73.
38. Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig
PU, Kramer PA. Toxic interaction between acetazola-
mide and salicylate: case reports and a pharmacokinetic
explanation. Clin Pharmacol Thera 1986; 40: 518-24
39. Kobayashi H, Kobayashi K, Kiryu J, Kondo T. Pilocarpine
induces an increase in the anterior chamber angular width
in eyes with narrow angles. Brit J Ophthalmol 1999; 83:
553-8.
40. Sirois FJ. Pilocarpine psychosis. Psychosoma 2005; 46: 88.
41. Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma
management. Clinical pharmacological aspects. Drugs
Aging 1992; 2: 208-21.
42. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side
effects. Serum chemical analysis. Arch Ophthalmol 1977;
95: 1378-82.
43. Adkins JC, Balfour JA. Brimonidine. A review of its
pharmacological properties and clinical potential in the
management of open-angle glaucoma and ocular hyper-
tension. Drugs Aging 1998; 12: 225-41.
Heimildir